AUTHOR INDEX

Volume 22, 1992

Aass, N., 1057
Abe, M., 597, 601, 973, 1009
Abitbol, A. A., 175
Ablin, A. R., 13
Abrams, M. J., 607
Adams, G. E., 467, 473, 545, 707, 717
Ahmad, K., 1065
Ahn, D., 295
Akazawa, C. N., 1093
Akuta, K., 1009
Albright, N. W., 1093
Alexander III, E., 573, 577
Algazy, K., 791
Allalunis-Turner, M. J., 765
Anderson, R. F., 537, 553
Archambeau, J. O., 287, 311, 383
Ardalan, B., 511
Armour, E., 109
Ayyagari, S., 1043

Bacher, J. D., 65
Bagshaw, M. A., 999
Bailey, S. M., 649
Baillet, F., 1071, 1099
Bando, M., 561
Banerjee, S. S., 929
Barnes, W., 1105
Barrett, J. M., 1071
Barron, G. M., 765
Barton, J., 925
Battista, J., 159
Baumann, M., 1163
Beck-Bornholdt, H.-P., 1163
Bedford, P., 721
Bedwinek, J., 23
Belfi, C. A., 477
Bender, H., 225
Benedetto, P., 511
Beningo, K. A., 549
Benoliel, J., 897
Bensadoun, R.-J., 897
Benson, K., 191
Bergsagel, D. E., 859
Bertoni, F., 585
Brub, L. R., 817
Bhatia, S. P. S., 1043
Bhujwalla, Z. M., 95
Biaglow, J. E., 665, 671
Biedermann, K. A., 681
Binger, M., 713
Black, P., 225
Blattmann, H., 333
Bleehen, N. M., 443, 721, 953
Blomquist, E., 259
Bodell, W. J., 489
Bonner, J. A., 519
Bradley, F. C., 607
Brady, L. W., 225
Breccia, A., 585
Bremner, J. C. M., 467, 717
Brenner, D. J., 221
Britten, R. A., 769
Brock, W. A., 241
Brown, J. M., 79, 553, 681, 701, 759
Brucher, J.-M., 275
Brunel, P., 1071, 1099
Bruton, C., 23
Bujnoski, J. L., 175
Bump, E. A., 731
Bush, R. S., 847, 853, 859
Bush, S., 935
Busutti, L., 585
Buswell, L., 565, 573, 577

Camel, H. M., 905
Carlsson, J., 259
Caruso, F. S., 607
Castro, R., 295
Cattanach, B. M., 473
Cerce, B. A., 731
Chang, F., 191
Chang, P., 191
Chaplin, D. J., 451, 459, 463, 685, 737
Charreau, I., 581
Chassagne, D., 581
Chatham, J. C., 95
Chen, G., 1075, 1164
Chen, M.-S., 913
Cheng, E., 1083
Choi, N. C., 1162
Cholon, A., 759
Chow, C. H., 167
Christensen, K. L., 451, 455
Christianson, T. J. H., 519
Chu, G. L., 1093
Chua, T., 859
Clark, R. M., 859
Clegg, S., 989
Cline, J. M., 403
Clubb, B., 1065
Cobb, L. M., 655
Cohen, A. M., 139
Coia, L., 791
Cole, S., 545, 707, 717
Coleman, C. N., 483, 565, 569, 573, 577, 731
Collier, J. M., 295
Comis, R., 791
Connor, A. M., 807
Constantinidis, I., 95
Coray, A., 333
Corry, P., 109
Cosmatos, D., 569
Counsell, C. J. R., 467
Cowan, D. S. M., 541
Cox, R. S., 999
Crowell, C., 305
Cummings, B. J., 833
Cuscela, D., 803

Dadparvar, S., 225
Daftari, I., 295
Dale, P., 813
Darcourt, J., 897
Darling, J. L., 103
Davis, L. W., 569
Davis, M. A., 499
Davis, R. K., 181
Day III, R. S., 765
Dea, D., 1093
Degraff, W. G., 593
Delanian, S., 1071, 1099
DeLaPaz, R. L., 47
Delclos, L., 941
Delgado, G., 1105
DeLuca, A. M., 65
Dembo, A. J., 835, 847, 853, 859, 867
Denekamp, J., 437
De Neve, W., 224
Dennis, I., 721
Dennis, M. F., 485, 751
Denny, W. A., 537, 553, 693
DeVol, E., 1065
Dewhirst, M., 989
Dobler, K., 765
Dobrowsky, E., 875
Dobrowsky, W., 875
Dobson, H., 1065
Dodge, R. K., 989
Douple, E. B., 607
Dowsett, R. J., 1083
Dritschilo, A., 1105
Dubray, B. M., 241
Durán, G. E., 821
Durand, R. E., 689
Duthie, M. B., 929

Edwards, D. I., 661, 677
Edwards, H. S., 717
Einhorn, L. H., 17
Ekwelundu, E., 167
El-Akkad, S., 1065
Ellerbroek, N., 1164
Elliott, W., 545, 549
Emami, B., 1163
Emrich, J., 225
Eng, T. Y., 1093
Enker, W. E., 139
Ensminger, W. D., 499
Epperson, R., 1083
Eschwege, F., 581
Eshleman, J., 225
Evans, M. L., 199
Ezz, A., 159

Fabrikant, J. I., 47
Falcone, F., 585
Falk, S. J., 721
Farah, S., 817
Fenster, A., 159
Fenton, B. M., 447
Ferri, E., 585
Fessenden, P., 999
Feun, L., 511
Fielden, E. M., 545, 707
Fieldler, J. A., 175
Fine, S., 853
Fischer, J. J., 87
Fitzpatrick, P. J., 859
Fornander, T., 887
Fortan, L., 224
Fossa, S. D., 1057
Fowler, J. F., 219, 1163
Frankel, J., 139
Frankel, K. A., 47
Frhling J., 979
Fyles, A. W., 833, 847, 867

Gademann, G., 375
Galakatos, A. E., 905
Galvin, J. M., 1083
Garcia, D. M., 905
García-Angulo, A. H., 589
Garg, P. K., 593
Garg, S., 593
Gasperin Jr., P., 979
Gauger, G., 295
Geard, C. R., 495, 613
George, S. L., 989
Giaccia, A. J., 681, 759
Giandomenico, C. M., 607
Ginsberg, M. S., 175
Glass, J., 803
Glatstein, E., 195
Gleave, E. N., 925
Glickson, J. D., 95
Goffman, T. E., 195, 803
Golden, R. N., 755
Goliaei, B., 1029
Gospodarowicz, M. K., 833, 859, 1161
Gottlieb, C., 505
Gozy, M., 979
Graham, M. M., 199
Grant, W., 989
Grau, C., 115, 407, 415, 421
Grdina, D. J., 813
Greer, S., 505
Gregroire, V., 275
Greiner, R. H., 333
Grierson, J. R., 199
Griffin, T. W., 199
Grigsby, P., 577, 905, 1117
Grisell, D. L., 65
Grunbaum, Z., 755
Guichard, M., 949
Gupta, B. D., 1043
Gutin, P., 295
Guttenberger, R., 795
Gyergyay, F., 785

Hacker, T., 655
Hahn, S., 803
Halberg, F. E., 13
Hale, R. J., 929
Hall, E. J., 221, 613, 743, 747
Hamada, K., 31
Hamamoto, K., 31
Hanks, G., 791

Harmer, C., 919
Harnsberger, H. R., 181
Harrelson, J., 989
Harrington, F. S., 195
Harris, J. R., 577
Harris, R., 1083
Hassenbusch, S. J., 477
Hayes, J. K., 181
He, S., 799
He, Z. Y., 747
Heffner, T. G., 549
Hei, T. K., 743, 747
Held, K., 665
Hendry, J. H., 241
Henkelman, R. M., 251
Henze, G., 1083
Hickson, I., 759
Hill, S. A., 437
Hinz, J. M., 623
Hiraoka, M., 1009
Holloway, R., 1105
Holman, M., 1089
Honess, D. J., 443, 953
Hong, J.-H., 913
Hori, H., 561
Horsman, M. R., 415, 421, 451, 455, 459
Host, H., 1057
Houdek, P. V., 175
Housset, M., 1071, 1099
Howes, A. E., 577
Hoyt, W. F., 1093
Huart, J., 1071, 1099
Hughes, C. S., 87
Hunter, N. R., 795
Hurwitz, S. J., 573, 577

Iketani, H., 31
Inayama, S., 561
Irvin, C. G., 87
Ishikawa, T., 321
Ito, T., 601
Iwata, K., 1109

Jaffray, D. A., 159
Jo, S., 1009
Johansson, H., 887

Kagiya, V. T., 589, 597, 601
Kahn, J., 1019
Kanagasabapathy, V. M., 541
Kann, R., 333
Kao, M.-S., 905
Kapp, D. S., 999
Kataoka, M., 31
Kawamura, M., 31
Kelley, M., 87
Kelsen, D. P., 139
Kemeny, N., 139
Khan, K., 935
Khil, M. S., 515
Kijewski, P., 325
Kim, J. H., 425, 515
Kim, R. Y., 1051
Kim, S. H., 515
Kim, Y. T., 623
Kinsella, T. J., 65
Kiss, R., 979
Kitagawa, T., 321
Klein, J. L., 37
Kligerman, M. M., 799
Kochhar, R., 1043
Koh, W.-J., 199
Kolozsvary, A., 515
Komaki, R., 1164
Kooistra, K. L., 713
Koprowski, H., 225
Kovacs, M. S., 681
Kramer, J. H., 13
Kramer, R. A., 573, 577
Krigel, R., 791
Krishna, C. M., 803
Krishnasamy, S., 1075
Kristjansen, P. E. G., 451
Kristl, J., 737
Krohn, K. A., 199, 755
Kuten, A., 905
Kuwahara, G., 1093
Kwok, T. T., 411, 525

LaDine, J. K., 403
Lagrange, J.-L., 897
Landy, H. J., 175
Lane, R. G., 167
Langer, M., 325
Larson, D. A., 1093
Lartigau, E., 949
Lau, D. H-M, 821
Lavey, R. S., 3
Lawrence, T. S., 499, 519
Lax, I., 887
Lazzaro, B., 225
Leavitt, D. D., 181
Lee, D.-J., 569
Lee, E. R., 999
Lee, I., 425
Lee, L., 23
Leichner, P. K., 37
Lemmon, M., 79, 701
Leopold, K. A., 989
Leopold, W., 545, 549
Lespinasse, F., 949
Lester, S. G., 17
Levin, C. V., 355
Levin, W., 847, 867
Levitt, S. H., 123, 425, 1157
Lewellen, T. K., 199
Lewin, A. A., 175
Lewis, A. D., 759, 821
Li, Y. P., 1009
Li, Z., 1089
Lichter, A. S., 361, 1147
Lin, F.-J., 913
Lin, J.-C., 123
Lindstrom, M. J., 1163
Linggood, R., 265
Linstadt, D. E., 295
Liu, F.-F., 223
Liu, T., 799
Liu, Y., 799
Livesey, J. C., 755
Livingstone, A., 511
Lo, E. H., 47
Lo, Y.-C., 57
Loeffler, J. S., 573, 577
Logue, J. P., 929
Low, N., 1075
Loyd, M. D., 167
Lupton, G., 803
Lyman, J. T., 247

MacPhail, H. S., 533
MacVittie, T. J., 773
Majima, H., 1019
Malaise, E. P., 581
Manchul, L. A., 847, 867
Mao, H.-S., 115
Marcial, V. A., 569
Marienberg, E. S., 175
Marijnissen, J. P. A., 963
Marion, H. S., 505
Markoe, A. M., 175
Martinez, A. P., 701
Martinez, A., 109
Masunaga, S.-I., 973, 1009
Masuoka, M., 597
Matsu-Ura, S., 31
Matthay, K. K., 13
Mauch, P., 1159
Maulard, C., 1071, 1099
Maybaum, J., 499
McArthur, P., 1065
McBride, W. H., 57
McClelland, R. A., 541, 817
McCormack, T., 225
McCulloch, W., 791
McDonald, S., 147
McElligott, M. A., 607
McGinnis, D. J., 731
McMillan, T. J., 103
McShan, D. L., 361
Mechling, J. A., 131
Meek, A. G., 1139
Meigooni, A. S., 1125, 1131
Meistrich, M. L., 71
Melillo, A., 1131
Mendenhall, W. M., 3
Menke, D., 79
Meredith, R. F., 1051
Meyer, J. L., 999
Migneco, O., 897
Milas, L., 795
Miller, A., 147
Miller, D. W., 383
Miller, R. W., 195
Minchinton, A. I., 79, 681, 701
Minsky, B. D., 139
Miralbell, R., 305
Mitchell, J. B., 483, 593, 665, 671, 803
Miyamoto, C., 225
Miyata, Y., 557
Mizuno, M., 451
Moeller, J. H., 181
Molteni, A., 623
Moore, I. M., 13
Moore, S. K., 727
Morabito, M., 225
Mori, T., 557
Morita, S., 321, 1047
Morphis II, J. G., 17
Morrell, L., 511
Mukai, M., 1047
Munkel, G., 333
Munro, A. J., 859
Munro, P., 159
Murayama, C., 557
Murray, J. C., 431
Myrianthopoulos, L., 1075, 1164

Nagasawa, H., 561
Nagata, Y., 1009
Nair, S., 225
Nath, R., 1125, 1131
Naylor, M. A., 707
Neben, T. Y., 573, 577
Needham, M., 1083
Negi, P. S., 1043
Nethersell, A. B. W., 721
Ngo, F. Q. H., 477
Nielsen, J. E., 407
Nieves, J., 225
Nishimoto, S.-I., 597, 601
Nishimura, Y., 1009
Nishiyama, Y., 31
Nolan, J., 655
Noll, L., 565, 577
Notarus, M. I., 383
Nowakowski, V. A., 295

O'Brien, P. J., 639
O'Hara, J. A., 607
Ohishi, H., 1109
Oleson, J. R., 989
Olive, P. L., 397, 689
O'Neill, P., 707
Ono, K., 973
Onoyama, Y., 561
Onyekwere, O. C., 37
Orr, K., 195
Orton, C. G., 222
Osborne, S., 159
Otsuka, M., 71
Overgaard, J., 115, 407, 415, 421, 451, 455

Pai, S., 1139
Pass, H. I., 65
Pasteels, J.-L., 979
Patchen, M. L., 773
Patel, F., 1043
Patterson, B. J., 859
Pauwels, O., 979
Payne, D., 223
Payne, R., 1083
Peacock, J. H., 103, 769
Pedroni, E., 333
Perez, C. A., 905, 1117
Peters, C. E., 463
Peters, G. E., 1051
Peters, G. J., 785
Peters, L. J., 941
Peters, N., 919
Peters, R., 791
Peterson, M. A., 1083
Petti, P. L., 295
Petty, A., 23
Phillips, T. L., 295, 489, 569
Piao, C. Q., 747
Pinedo, H. M., 785
Pirkowski, M., 1105
Pisciotta, V., 175
Pollart, D. J., 701

Popescu, G., 1105
Porter, A. T., 159
Porter, E., 87
Powell, S., 919
Preston, W., 383
Pringle, J. F., 847, 853, 867
Prionas, S. D., 999
Prosnitz, L. R., 989
Pryzant, R. M., 941
Purdy, J. A., 147

Quadri, S. M., 37
Quinney, R. M., 473
Quistorff, B., 451

Raaphorst, G. P., 1035
Rabbani, A., 1029
Rackover, M., 225
Rajabi, H., 1029
Raleigh, J. A., 403
Ramsay, J. R. S., 721
Rasey, J. S., 199
Rasmussen, J., 489
Rathman, M., 403
Rauth, A. M., 541, 817, 875
Rawlings, G. A., 847, 853, 867
Reddy, R., 511
Reinstein, L. E., 1139
Reynolds, A., 1083
Richardson, M. E., 781
Richman, S., 511
Riechman, B., 139
Riese, N., 565, 573, 577
Roberts, P. B., 537, 553
Rockwell, S., 87
Rodgers, J., 1105
Rose, M.-A., 565
Rosen, I. I., 167
Ross, G. Y., 489
Roth, B. J., 213
Rozec, C., 1071, 1099
Rubin, P., 1, 147, 569, 831
Rutqvist, L. E., 887
Ryan, T. P., 131

Sakaguchi, M., 557
Salter, M. M., 1051
Saltz, L., 139
Samulski, T., 989
Sancho-Garnier, H., 581
Sandler, H. M., 361
Sansom, J. M., 473
Santos, O., 505
Sasai, K., 597, 601
Sato, C., 557
Satoh, T., 561
Savaraj, N., 511
Scavone, S. V., 619
Scheffler, B., 799
Schien, P., 791
Schiff, P. B., 613
Schultheiss, T. E., 241
Schultz, H. P., 1065
Schwade, J. G., 175, 505
Sebolt-Leopold, J., 545, 549, 619
Serago, C. F., 175
Sethi, T., 1043
Shankland, E. G., 755
Shao, Y., 37
Share, F., 191
Shargel, L., 573
Sharma, S. C., 1043
Shaw, E. G., 1161
Shibamoto, Y., 597
Shirai, A., 1109
Shoji, T., 557
Siemann, D., 391, 393, 629, 697, 781
Sigdestad, C. P., 807
Sigurdson, E. R., 139
Sikic, B. I., 821
Silva, J. M., 639
Simm, J., 847, 853, 867
Simpson, J. R., 905
Sims, C. S., 807
Sindelar, W. F., 65
Singh, D. P., 1043
Singh, M. T., 1043
Skarsgard, L. D., 737
Skinner, A. L., 1083
Skov, K. A., 533
Skwarchuk, M. W., 737
Slater, J. D., 287, 311, 343, 383
Slater, J. M., 287, 311, 343, 383
Slessinger, E. D., 1117
Slevin, N. J., 925
Smee, R., 223
Smit, B., 343
Smith, K. A., 431
Smith, R., 1083
Sofield, J., 23
Song, C. W., 123, 425
Sougawa, M., 1019
Souza, L. M., 773
Spears, W. T., 17
Spencer, S. A., 1051
Star, W. M., 963
Steel, G. G., 103
Steinberg, G. K., 47
Stephens, M. A., 707
Steplewski, Z., 225
Stetson, P. L., 499
Stewart, A. L., 929
Stidley, C., 935
Stier, M. A., 549
Stinson, R. L., 37
Stone, H. B., 79
Storme, G., 224
Stratford, I. J., 467, 473, 529, 545, 707, 717
Stratford, M. R. L., 485, 751
Stridhar, K., 511
Strohbehn, J. W., 131
Sturgeon, J. F. G., 847, 853, 867
Sugget, N., 643, 649
Sugita, T., 597
Suit, H. D., 233, 305
Sur, R. K., 1043
Sutcliffe, S. B., 859, 1161
Sutherland, R. M., 411, 447, 525
Suto, M., 545, 549
Sutton, H., 1075
Suzuki, A., 557
Suzuki, T., 557

Tada, T., 561
Takahashi, M., 1009
Tamada, T., 1109
Tanabe, Y., 557
Tang, S. G., 913
Tangeman, R., 287
Tannock, I. F., 881
Tatsuzaki, H., 265, 369
Taylor, J. M. G., 3
Tefft, M., 477
Thames, H. D., 241
Thomas, C., 467
Thomas, D., 1105
Thomas, G. M., 847, 853, 867
Thompson, W., 935
Thrall, D. E., 403
Thum, P., 333
Ting, L.-L., 477
Tishler, R. B., 495, 613
Tocher, J. H., 661
Tochner, Z. A., 65
Tomiyama, T., 1109
Torrisi, J., 1105
Tosto, L. M., 681, 701
Tracy, M., 701
Treskes, M., 785
Trotter, M. J., 397
Ts'ao, C.-H., 623
Tsang, R., 859
Tsuji, Y., 1109
Tsujii, H., 321
Tsunemoto, H., 321, 1047
Tucker, J. A., 989
Tucker, S. L., 241
Tuttle, S. W., 671

Uchida, H., 1109
Uhl, V., 489
Urano, M., 1015, 1019
Urie, M. M., 265, 369
Urtasun, R. C., 235, 765
Uto, F., 1109

van de Geijn, J., 195
van der Vijgh, W. J. F., 785
van der Wilt, C. L., 785
Van Houtte, P., 979
van Laar, J. A. M., 785
van Putten, W. L. J., 963
van Zijl, P., 693
Varnes, M. E., 671
Versteeg, J. A. C., 963
Vijayakumar, S., 1075, 1164
Vikse, C., 397
Vincent, P. W., 549
Vinczan, A., 737
Virk, N. S., 677
Vitu, L., 949
Vriesendorp, H. M., 37

Wada, T., 1109
Wahlen, S., 343
Waldman, S., 511
Wallen, C. A., 727
Walton, M. I., 643, 649
Wambersie, A., 275
Wang, C. C., 1155
Wang, J., 601
Wang, Z., 109
Wannenmacher, M., 375
Wara, W. M., 13, 1093
Ward, R., 721
Ward, W. F., 623
Wardman, P., 537, 751
Warenius, H. M., 769
Wasserman, T. H., 391, 569, 629
Watts, M. E., 431
Wehrle, J. P., 95
Weichselbaum, R., 813, 1164
Weinhous, M. S., 1089
Wen, P., 577
Wendt, C. D., 941
Weppelmann, B., 1051
Wheeler, K. T., 727
Wheeler, R. H., 1051
Whelan, T. J., 853
White, J., 537, 751
White, R., 769
Wiley, J. N., 549
Willett, C. G., 369
Williams, J. R., 37
Williams, K. B., 437
Williams, S. D., 17, 213
Williamson, J. F., 1117
Wilson, D. J., 737
Wilson, W. R., 537, 553, 693
Withers, H. R., 57
Woo, D. V., 225
Wood, P. J., 467, 473
Woodcock, M., 431
Wootton, R., 721
Workman, P., 391, 629, 631, 643, 649, 713, 721
Wu, X., 175
Wyman, M., 755

Yabuki, H., 87
Yamamoto, I., 1109
Yang, X., 103
Yoshimura, H., 1109

Zalutsky, M. R., 593
Zeman, E. M., 403
Zhang, Z., 799
Zhou, L., 597
Zusag, T. W., 147

SUBJECT INDEX

Volume 22, 1992

A

Accelerators, 383
ACE inhibitors, 623
Acid
  Ethacrynic, 821
  Flavone acetic, 79, 431, 437
  Hydroxamic, 561
  N-(phosphonacetyl)-L-aspartic, 505
Abnormal large nuclei, 71
Acridine, 553
  Orange, 537, 751
Adjuvant therapy, 139
Adriamycin, 459
Adverse effects, 949
A549
  Cells, 489
  Human carcinoma, 665
Afterloading, 1105
  High dose rate, 23
  Ir-192, 1071
Age, 919
Agent(s)
  Antiemetic, 549
  Bis-bioreductive, 693
  Radiation-protective, 807
AK-2123, 589
Alkylating agent, 619
Alopecia, 803
Alpha-beta ratio, 3
Amino acid analogue, 593
Am-241, 1125
Analogues, 701
Analysis
  Digital cell image, 979
  Sensitivity, 325
Animal tumors, 607
Antiemetic agents, 549
Antimutagen, 813
Assay
  Endogenous-spleen-colony, 807
  Micronucleus, 973
Astrocytoma, 287
  High grade, 225
AZT, 813

B

Beagle dog, 37
Beam's eye section, 1089
BES, 1089
Bioreduction, 545, 677
Bioreductive
  Alkylation, 639
  Compounds, 697
  Cytotoxin, 701
  Drugs, 631, 689, 707, 717, 747
Bis-bioreductive agent, 693
Blood-brain barrier, 47
Blood flow, 415, 421, 447
  Regional cerebral, 47
  Tumor, 459, 463, 467
Blood perfusion, 451
  Tumor, 477
Blood pressure, 451, 455
  Mean arterial, 79
BL-10, 681
BNCT, 259
Bolus material, 191
Bone marrow transplatation (BMT), 37
Borderline epithelial ovarian neoplasms, 867
Boron neutron capture therapy, 259
Brachytherapy, 181, 573, 577, 905, 1071, 1117, 1125, 1131
  Endobronchial, 23
Brain, 47
  Metastasis, 17
  Neoplasm, 225
  Tumors, 573
Brain/plasma partition coefficient, 601
Breast cancer, 887, 1099
Bromodeoxyuridine, 485
  Sensitization, 495
BSO, 533, 593, 681
BUdR, 485
BUN, 71
Buthionine sulfoximine, 519, 765, 781
BW12C, 721

C

Calcium channel blockers, 443
Cancer(s)
  Breast, 887, 1099
  Cervical, 919
  Esophageal, 1043, 1047
  Gastrointestinal, 721
  Head and neck, 3, 181, 1065
  Lung, 1009
  Ovarian, 835, 847, 853
  * Prostate, 935
  Rectal, 139, 1109
  Recurrent head and neck, 1051
  Testicular, 1057
  Uterine cervix, 589
Canine tumors, 403
Kaptopril, 623
Carbogen, 415
Carbon monoxide, 421
Carboxyhemoglobin, 407, 421
Carcinogenesis, 795
Carcinoma(s)
  A549 human, 665
  Cervix, 349
  C3H mammary, 115
  C3H mouse mammary, 451, 455
  Endometrial, 905
  Esophageal, 321
  Head and neck, 581
  Human squumous cell, 525
  In vivo C3H mammary, 415, 421
  Lewis lung, 505
  Lung, 65, 585
  Nasopharyngeal, 941
  Ovarian, 1105
  Rectal, 369
  Squamous cell, 407
  Uterine cervix, 31
Cardiac function, 897
Cardiovascular disease, 887
Carotid
  Body, 919
  Cannulation, 455
CB 1954, 643
CCI-103F, 403
CDF1 mice, 451, 455
Cell(s)
  A549, 489
  Cervical carcinoma, 495
  Cycle, 525, 613
  HeLa, 515
  Hypoxic, 557, 607
  L5178Y, 639
  Mammalian, 533
  Quiescent, 973
  SCC VII-To, 875
  U87 mg, 489
  U1, 489
Cell, hypoxic, 557, 607
  Sensitizer, 569, 573, 577, 581, 593
  Toxicity, 817
Cellular
  Radiosensitivity, 769
  Recovery, 103
Central nervous system, 287
Cervical
  Cancer, 919
  Carcinoma cells, 495
  Lymphadenopathy, 1071
Cervix, 343, 355
  Carcinoma, 349
Charged particle(s), 311, 383
  Radiotherapy, 295, 375
Chemical
  Modifiers, 573, 577
  Response modifiers, 585
Chemodectoma, 919
Chemopotentiation, 619
Chemosensitization, 727
Chemosensitizer, 765
Childhood, 287
Chlorambucil cytotoxicity, 737
Cinnarizine, 443
Cisplatinum, 459, 785
Clinical correlation, 235
Coagulation, 431
Cognitive function, 13
Collateral resistance, 769
Combination therapy, 1047
Combined
  Modality therapy, 835, 853
  Treatment, 999
Comparative treatment planning, 265, 305, 369
Complication(s), 311, 343, 847, 853, 999, 1043
  Late, 3
Computed
  Tomography (CT), 181
  Tomography-emission, 195
  Tomography-x-ray, 195
Computer-assisted, 195
Computer-controlled
  Radiation therapy, 167
  Stereotaxic guide, 175
Computer
  Graphics, 147
  Workstation, 147
Conformal therapy, 325
Continuous infusion, 573, 577
Contrast media, 477
Copper complexes, 607
Cs-137, 1125

C3H mammary carcinoma, 115
In vivo, 415, 421
C3H mouse mammary carcinoma, 451, 455
CT simulator, 175
Cumulative minutes, 989
Cyanomorpholino doxorubicin, 821
Cyclophosphamide, 727
Cystafos, 807
Cysteine, 751
Cytotoxicity
Chlorambucil, 737
Hypoxic cell, 697

D

Damage
DNA, 677
Inhibition of repair of sublethal radiation, 1035
Oxidative, 677
Repair of potentially lethal, 973
Delayed
Fluorescence, 537
Radiation injury, 47
Depth dose, 235
Design and development, 383
Diamide, 671
Diaphragmatic metastases, 1105
Diaziridinyl benzoquinones, 649
Dicumarol, 655
Digital cell image analysis, 979
Disease
Cardiovascular, 887
Hodgkin's, 37, 859
DNA, 485, 537, 751
Bases, 661
Binding, 693
Damage, 677
Intercalation, 553
Nucleosides, 661
Strand breaks, 677
Targeting, 541
Dose-volume histogram, 1093
Dose(s)
Calculations, 1131
Depth, 235
Low, 533
Dose effect, 1043
Relationship, 963
Dosimetry, 147, 191, 1117, 1131
In vivo, 1109
Thermal, 989
Doxorubicin, 519
Drug(s)
Bioreductive, 631, 689, 707, 717, 747
Radiation, 875
Resistance, 639
DT-diaphorase, 639, 643, 649
Dynamic, 333

E

Early effects, 897
Education, 147
Effect(s)
Adverse, 949
Chlorambucil and hydralazine on mouse tumors (SCCVII), 737
Dose, 1043
Early, 897
Late 65
Long-term, 887
Low pH, 737
Radiation, 807
Tumor bed, 963
Volume, 57
EGF, 259
86-RbCl, 421
Extraction technique, 415
Elasto-gel, 191
Electron
Capture, 537
Energy, 191
Spin resonance, 803
ELISA, 403
Emesis, 549
EMT6, 553
Tumor, 505, 557
Endobronchial brachytherapy, 23
Endogenous-spleen-colony assay, 807
Endometrial carcinoma, 905
Endothelial, 431
Endothelium, 623
Energy
Electron, 191
Photon, 191
Enzymes, 631
Enzymology, 643
EO9, 643, 713
EPID, 1139
Epidermal growth factor, 225, 259, 525
Esophageal
Cancer, 1043, 1047
Carcinoma, 321
Etanidazole, 557, 565, 569, 573, 577, 585, 731, 743
Ethacrynic acid, 821
Ethiofos, 807
Evoked potentials, 47
External beam irradiation, 1043

F

Factor(s)
Epidermal growth, 525
Granulocyte colony-stimulating, 773
Predictive, 999
Prognostic, 859
Failure pattern, 859
Field study, 375
Finite elements, 131
Fission spectrum, 807
5-chloro-2′-deoxycytidine, 505
5-fluoro-2′-deoxyuridine, 499
5-fluorodeoxycytidine, 505
5-fluorouracil, 499, 785, 875, 1051
5-hydroxytryptamine, 463
5-iodo-2′-deoxyuridine, 499
Flavone acetic acid, 79, 431, 437
Flunarizine, 443, 473
Fluorescent
Derivative, 485
Probes, 751
Fluorinated 2-nitroimidazole, 593
Fluorine-modified nitroazole, 601
fluoromisonidazole, 199
Foot reaction, 1015
4-bromomethyl-7-methoxycoumarin, 485
14-C-deoxyglucose autoradiography, 95
Fractionated radiotherapy, 259
Fractionation, 3, 109, 415
Free radicals, 677
FSa-II tumor, 1019
FU/LV/PALA, 511
Function
Cardiac, 897
Cognitive, 13
Radial dose, 1125
Renal, 443

G

Gadopentetate dimeglumine, 477
Gastrointestinal cancer, 721
Glioblastoma multiforme, 265
Glioma(s), 103, 259, 287
Malignant, 259, 765
Glomus jugulare, 919
Glucose, 95
Glucose-6-phosphate dehydrogenase, 671
Glutathione, 665
Depletion, 533
Hydroperoxides, 671
Peroxidase, 665, 751, 781, 817
Glutathione-S-transferase, 665, 759, 821
Granulocyte colony-stimulating factor, 773
GR63178, 437
GSH, 681
Depletion, 821
Gynecological malignancies, 1117

H

Head and neck, 407
Carcinoma, 581
Recurrent cancer, 1051
Head and neck cancer(s), 3, 181, 1065
Recurrent, 1051
Heat, 115
Heavy ions, 321
HeLa cells, 515
Hematoporphyrin derivative, 963
Hemoglobin, 407
Level, 919
Hemopoiesis, 773
Heterogeneity, 103
HGPRT, 813
High dose rate
Afterloading, 23
Irradiation, 31
High grade astrocytoma, 225
High LET, 295
Hodgkin's disease, 37, 859
HPLC, 485, 553
Human, 225
Cell lines, 769
Glial tumors, 613
Squamous cell carcinoma, 525
Hydralazine, 79, 455, 463, 467, 473, 477, 953
Hydroperoxides, 665
Glutathione, 671
Hydroxamic acid, 561
Hydroxyurea, 1051
Hypercard, 147
Hyperthermia, 109, 115, 123, 131, 989, 999, 1009, 1035
Hyperthermia and radiation, 1015
Hypoxia, 115, 411, 545, 589, 689, 717, 721, 731, 747
Markers, 403
Tumor, 199, 397
Hypoxic, 701
Fraction, 415, 421
Hypoxic cell(s),557, 607
Cytotoxicity, 697
In solid tumors, 87
Radiosensitizer, 561, 597
Sensitizer(s), 569, 573, 577, 581, 593
Toxicity, 817

I

Ifosfamide, 727
Image correlation, 195
Imaging, 1139
  Magnetic resonance, 477
  Oncological, 251
  On-line, 1139
  Portal, 159
  Therapy, 159
  Video-based portal, 159
Immunofluorescence staining, 973
Immunotherapy, 225
Implants
  Interstitial, 1131
  Permanent, 1131
Incorporation, 485, 489
Index
  Labeling, 71
  Therapeutic risk, 601
Indoloquinone(s), 649, 713
Indwelling intra-uterine tube, 349
Infra-diaphragmatic radiotherapy, 1057
Inhibition of repair of sublethal radiation damage, 1035
Insertion depth, 131
Integration of diagnostic and therapeutic procedures, 175
Interactions, 875
Interferon, 765
Internship and residency, 1147
Interstitial
  Implants, 1131
  Light delivery, 963
Intracavitary
  Irradiation, 31, 1043, 1117
  Radiation therapy, 1109
  Therapy, 349
Intracellular
  Concentrations, 751
  Drug concentration, 541
Intraoperative, 1105
  Irradiation, 65
Intratumor pH, 123
In vitro, 875
In vivo, 115
  C3H mammary carcinoma, 415, 421
  Dosimetry, 1109
  Light dosimetry, 963
Iodine-125, 225, 1125, 1131
Iododeoxyuridine, 489
Ionizing radiation, 671, 759
Iridium-192, 181, 935, 1099, 1125
  Afterloading, 1071
Irradiation
  External beam, 1043
  High dose rate, 31
  Intracavitary, 31, 1043, 1117
  Intraoperative, 65
  Low dose rate, 109, 495
  Pion, 333
  Preoperative, 905
  Prophylactic cranial, 13
  Proton, 259
  Total body, 791

K

KHT, 781
  Sarcoma, 477
  Tumor, 953
Kidney, 953
  Function, 953
  Mouse, 71
  Weight, 71
KIH-802, 561
KIIH-802, 561
KIN-804, 561
KIN-831, 561

L

Labeling index, 71
Lactate, 95
Laser Doppler, 455, 459, 463
Late
  Complications, 3
  Effects, 65
  Radiation damage, 71
Late-responding tissue, 1015
Leukemia, 13
Lewis lung carcinoma, 505
L5178Y cells, 639
Liver, 953
Local
  Control, 311, 343
  Recurrence, 1099
Long-term effects, 887
Low dose(s), 533
  Rate irradiation, 109, 495
Low pH effect, 737
  On chlorambucil uptake, 737
Lung
  Cancer, 1009
  Carcinoma, 65, 585
  Injury, 623
Lymphoma, 791, 929

M

Magnetic resonance, 251
  Imaging, 477
Magnetic resonance spectroscopy (MRS)
  19-F, 467
  Nuclear, 755
  31-P, 467, 473
Malignant glioma(s), 259, 765
Mammalian cells, 533
Maxillary sinus, 305
Mean arterial blood pressure, 79
Mechanisms, 631
Medical eduction, 1147
Melphalan, 731, 769
Meningioma, 1093
Metabolic rate, 597
Metabolism, 631
  N-oxide, 693
  Tumor, 451, 467
Metal, 607
Metastasis(es)
  Brain, 17
  Diaphragmatic, 1105
Meth-A tumor, 515
Metronidazole, 661
Mice, 807, 949
  CDF1, 451, 455
Micronucleus assay, 973
Microwave antennas, 131
Miralva, 1117
Misonidazole, 115, 553, 795
Mitomycin C, 643, 721, 875
Modulation, 759
  Resistance, 821
Monoclonal antibody, 225
Morbidity, 925
  Interstitial implants of prostate, 935
Morphonuclear modifications, 979
Mortality, 887
Mouse, 57
  Kidney, 71
  Mammary tumor, MXT, 979
MTT, 655
MXT mouse mammary tumor, 979

N

Nasopharyngeal carcinoma, 941
Neoplasm(s)
  Borderline epithelial ovarian, 867
  Brain, 225
  Testicular, 17
Nephrectomy, 71
Neuropsychological, 13
Neurotoxicity, 565
Neutron(s), 807
  Therapy, 321, 1065
Nicotinamide, 79, 425, 451
Nifedipine, 443
19-F magnetic resonance spectroscopy (MRS), 467
Nitracrine, 693
Nitracrine-N-oxide, 693
Nitroacridines, 537
Nitroimidazole, 561
Nitro radical anion, 661
Nitroxide, 803
NLA-1, 553
Normal tissue(s), 655
  Tolerance, 65
N-oxide metabolism, 693
N-(phosphonacetyl)-L-aspartic acid (PALA), 505
Nuclear magnetic resonance spectroscopy, 755
Nude mouse, 37

O

OER, 533
OK-432, 1047
Oncogenic
  Potential, 747
  Transformation, 743
Oncological imaging, 251
On-line imaging, 1139
Optic nerve, 1093
  Sheath, 1093
Ovarian
  Cancer, 835, 847, 853
  Carcinoma, 1105
  Tumors of low malignant potential, 867
Oxidative
  Damage, 677
  Stress, 803
Oxygen, 415, 447
  Consumption tumor, 397
  Tension, 949
  Utilization, 407
Oxygenation, 451
  Tumor, 425

P

Palladium-103, 1131
Para-aortic lymph nodes, 355
Paralysis, 57
Paraspinal tumors, 295
Parotid pleomorphic adenoma, 925

Particle therapy, 349
Partition coefficient
Brain/plasma, 601
Tumor/plasma, 601
Pd-123, 1125
Pediatric, 287
Solid tumors, 375
Penetrating ability, 1125
Pentose cycle, 671
Pentoxifylline, 425
Perfluorochemical emulsions, 87
Perfluorooctylbromide, 87
Permanent implants, 1131
Permeability, 431
Peroxide, 665
Electrode, 665
p50, 407
PFOB, 467
pH, 95
Intratumor, 123
Pharmacokinetics, 561, 565, 701, 713
Phase I, 511
Phosphate metabolites, 95
Phosphorothioates, 807
Photodynamic therapy, 963
Photofrin II, 963
Photon(s), 769
Energy, 191
Pimonidazole, 553
Pion irradiation, 333
Polarographic method, 949
Poly(ADP-ribose) synthetase, 619
Portal, 1139
Aperture, 1089
Portal imaging, 159
Vidoe-based, 159
Positron emission transaxial tomography, 199
Potentially lethal damage repair, 973
Precision radiotherapy, 251
Predictive factors, 999
Predictor of response, 199
Preoperative irradiation, 905
Prognostic factors, 859
Prophylactic cranial irradiation, 13
Propranolol, 463
Prostate, 361
Cancer, 935
Proton(s), 287, 355, 343, 383
Beam therapy, 265, 305
Irradiation, 259
Radiation therapy, 369
Therapy, 321, 349

Q

Quality assurance, 159, 1139
Quiescent cells, 973

R

Radial dose function, 1125
Radiation, 415, 421, 795, 859, 875, 1047
Delayed injury, 47
Drug, 875
Effects, 807
Hepatitis, 37
Induced, 623
Ionizing, 671, 759
Late damage, 71
Lethality, 665
Protector, 799
Response, 411, 525
Sensitizer(s), 499, 565
Radiation and hyperthermia, 1015
Radiation-protective agents, 807
Radiation therapy, 31, 139, 847, 887, 897, 989, 1009, 1093, 1105
Computer-controlled, 167
Intracavitary, 1109
Proton, 369
Radiofrequency, 1009
Radioimmunoglobulin therapy (RIT), 37
Radioprotection, 773, 803
Radioresponse, 425
Radiosensitivity, 103, 1019
Cellular, 769
Radiosensitization, 489, 515, 533, 537, 545, 561, 589, 717, 1035
Radiosensitizer(s), 557, 573, 577, 585, 607, 613, 707, 765
Hypoxic cell, 561, 597
Radiosurgery, 47
Radiotherapy, 13, 115, 195, 287, 311, 343, 361, 383, 585, 835, 919, 925, 929, 979
Charged particle, 295, 375
Fractionated, 259
Infra-diaphragmatic, 1057
Localization, 159
Precision, 251
Stereotaxic, 175
3D conformal, 235, 333
Randomized trial, 581
Rectal cancer, 799
Rat, 37
Rectal cancer, 139, 1109
Randomized trial, 799
Rectal carcinoma, 369
Recurrence, 925, 941
Local, 1099
Recurrent
Head and neck cancer, 1051
Tumors, 1019
Redox cycling, 639
Reductases, 655
Reduction-oxidation state, 755
Regional cerebral blood flow, 47
Reirradiation, 1051
Renal function, 443
Reoxygenation, 411
Repair, 1015
Residency training in radiation oncology, 1147
Resident training, 147
Resistance
Collateral, 769
Drug, 639
Modulation, 821
Resonance
Electron spin, 803
Magnetic, 251
Response
Predictor, 199
Radiation, 411, 525
Re-treatment, 941
Retroperitoneal tumors, 375
Rhabdomyosarcoma R-1, 963
RIF-1 tumors, 95
Risk estimates, 743
Ro-03-8799, 459
RP-170, 557
RSU 1069, 459, 549

S

Salvage
Curietherapy, 1099
Therapy, 1071
Sarcoma(s), 989
KHT, 477
Unresectable soft tissue, 333
SCC VII, 553
Tumor, 557
SCC VII-To cells, 875
sc 9L tumor, 727
Sensitivity
Analysis, 325
Thermal, 1019
Sensitizer(s), 731
Hypoxic cell, 569, 573, 577, 581, 593
Radiation, 565
Side effects, 1057
Simulator, CT, 175
Skin, 115
Smoking, 407, 421
Sm-145, 1125
Spheroids, 689, 693
Spinal cord injury, 57
Spontaneous tumors, 473
Squamous cell carcinoma, 407
SR 4233, 643, 677, 681, 701
SR 2508, 565, 569, 573, 577, 593, 731
Stage, 919
Stereotaxic
Computer-controlled guide, 175
Radiotherapy, 175
Strand breaks, DNA, 677
Structure-activity relationships, 649
Sulfur-substituted 3-nitrotriazoles, 597
Surgery, 919, 925
Survival, 311, 431

T

Taxol, 613
Technique, 1093, 86-RbCl extraction, 415
Temperature distributions, 131
Temporary interstitial implantation, 935
Testicular
Cancer, 1057
Neoplasms, 17
Tetrahydrouridine, 505
T-50, 989
Therapeutic
Management, 867
Risk index, 601
Therapy
Adjuvant, 139
Boron neutron capture, 259
Combination, 1047
Combined modality, 835, 853
Conformal, 325
Imaging, 159
Intracavitary, 349
Neutron, 321, 1065
Particle, 349
Photodynamic, 963
Proton, 321, 349
Proton beam, 265, 305
Radiation, 31, 139, 847, 887, 897, 989, 1009, 1093, 1105
Radioimmunoglobulin, 37
Salvage, 1071
Thermal
Dosimetry, 989
Parameters, 999
Sensitivity, 1019
Thermoluminescent sheet, 1109
Thiols, 751, 755
13-C and 31-P NMR *in vivo*, 95

31-P magnetic resonance spectroscopy (MRS), 467, 473
Three-dimensional (3D)
  Conformal radiotherapy, 235, 333
  Treatment planning, 361
-misonidazole, 655
Thyroid, 929
Tissue(s)
  Late-responding, 1015
  Normal, 655
  Normal tolerance, 65
T-90, 989
Tolerance, 325
Tomography-emission computed, 195
Tomography-x-ray computed, 195
Tonsil, 311
Topoisomerase, 519
Topotecan, 515
Total body irradiation, 791
Transplantable tumors, 473
Treatment planning, 167, 181, 195, 325, 1131
  Comparative, 265, 305, 369
  Three-dimensional, 361
Trenimon, 639
Trial, Randomized, 581
T-10, 989
Tumor(s), 79, 701
  Animal, 607
  Bed effect, 963
  Blood flow, 459, 463, 467
  Blood perfusion, 477
  Blood volume, 467
  Brain, 573
  Canine, 403
  Control, 421, 963
  EMT-6, 505, 557
  FSa-II, 1019
  Heterogeneity, 765
  Human glial, 613
  Hypoxia, 199, 397, 403
  KHT, 953
  Metabolism, 451, 467
  Meth-A, 515
  MXT mouse mammary, 979
  Necrosis, 437
  Oxygenation, 87, 425
  Oxygen consumption, 397
  Oxygen unloading capacity, 407
  Paraspinal, 295
  Pediatric solid, 375
  Perfusion, 79
  Recurrent, 1019
  Regression, 919
  Retroperitoneal, 375
  RIF-1, 95
  SCC VII, 557
  sc 9L, 727
  Spontaneous, 473
  Transplantable, 473
  Vasculature, 397
Tumor/plasma partition coefficient, 601
T.V. cameras, 159
2-nitroimidazole(s), 403, 553, 565, 573, 577, 593, 727, 817
  Fluorinated, 593
  Linked phenanthridine, 541
  Nucleoside analog, 557

U

U87 mg cells, 489
Unresectable soft tissue sarcoma, 333
U1 cells, 489
Uterine cervix
  Cancer, 589
  Carcinoma, 31

V

Vaginal applicator, 1117
Vascular
  Thermotolerance, 123
  Tumor, 397
Verapamil, 443
Video-based portal imaging, 159
Volume effect, 57

W

WR-1065, 751
WR-151326, 813
WR-2721, 773, 785, 791, 795, 799

Y

Yb-169, 1125